Citius Oncology Soars 27.44% on Bullish Outlook

On June 25, 2025, Citius Oncology's stock surged by 27.44% in pre-market trading, marking a significant upturn in its performance.

Citius Oncology, Inc. is anticipated to achieve breakeven in the near future, making it an opportune time for analysis. The company's average price target is set at $6.00, which is 125.56% higher than its current price. The consensus rating among analysts is "Buy," indicating a strong bullish sentiment towards the stock.

On June 23, 2025, Citius Oncology experienced a notable decline of 16.35% in pre-market trading, reflecting the volatility in the biotech sector. This drop was followed by a significant rebound, as seen in the recent pre-market surge.

Analysts have provided a consensus rating of "Buy" for Citius Oncology, with a price target of $6.00, suggesting a potential upside of 140.00%. This positive outlook is likely contributing to the recent bullish momentum in the stock.